Landos Biopharma Inc (LABP)
22.46
+0.16
(+0.72%)
USD |
NASDAQ |
May 17, 16:00
22.46
0.00 (0.00%)
After-Hours: 20:00
Landos Biopharma Enterprise Value: 41.23M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 41.23M |
| May 16, 2024 | 40.70M |
| May 15, 2024 | 40.70M |
| May 14, 2024 | 41.17M |
| May 13, 2024 | 40.40M |
| May 10, 2024 | 40.80M |
| May 09, 2024 | 40.89M |
| May 08, 2024 | 40.40M |
| May 07, 2024 | 40.30M |
| May 06, 2024 | 40.23M |
| May 03, 2024 | 40.50M |
| May 02, 2024 | 40.40M |
| May 01, 2024 | 40.53M |
| April 30, 2024 | 40.55M |
| April 29, 2024 | 41.12M |
| April 26, 2024 | 40.59M |
| April 25, 2024 | 41.15M |
| April 24, 2024 | 40.18M |
| April 23, 2024 | 40.09M |
| April 22, 2024 | 39.49M |
| April 19, 2024 | 39.06M |
| April 18, 2024 | 38.84M |
| April 17, 2024 | 38.59M |
| April 16, 2024 | 38.12M |
| April 15, 2024 | 38.28M |
| Date | Value |
|---|---|
| April 12, 2024 | 38.12M |
| April 11, 2024 | 38.04M |
| April 10, 2024 | 38.10M |
| April 09, 2024 | 38.01M |
| April 08, 2024 | 38.01M |
| April 05, 2024 | 38.35M |
| April 04, 2024 | 38.01M |
| April 03, 2024 | 37.97M |
| April 02, 2024 | 38.07M |
| April 01, 2024 | 38.32M |
| March 28, 2024 | 29.45M |
| March 27, 2024 | 29.07M |
| March 26, 2024 | 29.70M |
| March 25, 2024 | 29.20M |
| March 22, 2024 | -13.10M |
| March 21, 2024 | -13.59M |
| March 20, 2024 | -15.71M |
| March 19, 2024 | -15.87M |
| March 18, 2024 | -16.80M |
| March 15, 2024 | -16.80M |
| March 14, 2024 | -17.30M |
| March 13, 2024 | -17.30M |
| March 12, 2024 | -17.15M |
| March 11, 2024 | -18.02M |
| March 08, 2024 | -18.05M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-49.56M
Minimum
May 25 2022
608.66M
Maximum
Mar 01 2021
89.18M
Average
-22.59M
Median
Jan 25 2024
Enterprise Value Benchmarks
| AbbVie Inc | 349.85B |
| Fusion Pharmaceuticals Inc | 1.669B |
| Masimo Corp | 7.314B |
| Kinnate Biopharma Inc (DELISTED) | -28.89M |
| Invivyd Inc | 96.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.897M |
| Total Expenses (Quarterly) | 9.295M |
| EPS Diluted (Quarterly) | -1.43 |
| Earnings Yield | -17.76% |